Thus, the molecular basis of ALL sensitivity to PIs is similar to MM, and solid tumors that express PTEN mutations, which lead to the activation of protein synthesis through the mTOR pathway70–73. The gene discussed is PTEN; the disease is acute lymphoblastic leukemia.